Atossa Therapeutics, Inc..
ATOS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics and delivery methods for breast cancer and other breast conditions. The company's primary focus is on developing and commercializing innovative therapies and delivery methods to improve b...Show More
Better Health for All
0
Atossa Therapeutics is entirely focused on developing therapeutics for breast cancer treatment and prevention.
1
Its lead product, (Z)-endoxifen, has demonstrated transformative health benefits, including more than doubling median Progression-Free Survival (PFS) compared to tamoxifen (7.2 vs. 2.4 months) in metastatic patients, achieving 5-year cancer-free survival in a patient, and significantly reducing mammographic breast density by up to 23.5 percentage points.
2
The company had approximately $57.9 million in cash and no debt as of June 30, 2025, indicating substantial investment in health innovation.
3
Clinical trials involving over 700 participants have shown (Z)-endoxifen to be well-tolerated, with early data suggesting a lower incidence of common SERM-related side effects compared to tamoxifen, and no significant differences in adverse events for the 1 mg dose compared to placebo in the KARISMA trial.
4
The company has an FDA-approved 'expanded access' program for seriously ill patients who have exhausted other options, and a regulatory strategy that could bring the product to patients years sooner at lower cost.
5
The company conducts clinical studies to understand potential risks and benefits and expects to update shareholders on FDA meeting outcomes.
6
However, the company's privacy policy indicates that it collects personal information through its website, including via a third-party provider, and stores all collected information in the United States, which may not align with global data protection standards.
7
While the company is developing a low-dose strategy for breast cancer risk reduction, there is no specific information on dedicated investment in preventative health measures as a percentage of health-related expenditure. The company acknowledges musculoskeletal symptoms associated with existing treatments, but there is no evidence of specific mental health initiatives.
8
The company holds four issued U.S. patents and numerous pending applications for (Z)-endoxifen, but there is no evidence of patent flexibility for global health needs.
9
Fair Money & Economic Opportunity
0
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for breast cancer.
1
The provided articles detail clinical trial programs, treatment updates, financial results, and patent filings, all within the pharmaceutical sector. The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to Atossa Therapeutics, Inc., as its operations fall outside the scope of financial services.
Fair Pay & Worker Respect
0
No evidence available to assess Atossa Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
Based on the provided articles, there is insufficient evidence to assess Atossa Therapeutics' performance regarding Fair Trade & Ethical Sourcing. The articles primarily discuss contracts for clinical trial services and legal matters, with no mention of supply chain practices, ethical sourcing policies, or related metrics.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
8
Given the company's business model as a clinical-stage biopharmaceutical company, its direct exposure to fair trade and ethical sourcing issues is likely lower, but without specific information, a neutral score is most appropriate. The materiality analysis confirms that the business model has neutral to low materiality regarding Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company's board consists of 7 members, with 5 determined to be independent, resulting in approximately 71.4% of board members being free from material conflicts of interest.
1
An anti-corruption policy is in place, covering business activities outside the U.S. and mentioning compliance with laws like the U.K. Bribery Act of 2010, but the frequency of training and effectiveness metrics are not specified.
2
For third-party verification, the company relies on third-party contractors for manufacturing and clinical studies, requiring them to be qualified by subject matter experts and meet compliance expectations.
3
However, the extent of independent verification of ethical claims is not quantified beyond these general statements.
Kind to Animals
-40
Atossa Therapeutics, Inc. conducts animal testing for some of its novel therapeutics and delivery methods.
1
These animal studies are performed in compliance with FDA's Good Laboratory Practice regulations and the U.S. Department of Agriculture’s Animal Welfare Act.
2
The company is listed on crueltyfreeinvesting.org as exploiting animals.
3
Nonclinical testing generally consists of safety, toxicology, and pharmacology studies in animals, with extensive nonclinical data required.
4
No War, No Weapons
0
No evidence was found in the provided articles to assess Atossa Therapeutics, Inc. against the 'No War, No Weapons' ethical value.
1
The articles primarily focus on corporate governance and legal policies for a pharmaceutical company and explicitly state that no data relevant to defense or peacebuilding activities is present.
2
Planet-Friendly Business
0
The provided article, a letter to shareholders, focuses on Atossa Therapeutics' 2024 accomplishments and 2025 outlook, primarily detailing clinical trial results and drug development milestones.
1
It does not contain any specific data or information regarding the company's environmental performance, such as greenhouse gas emissions, renewable energy use, water consumption, waste diversion, or any climate-related targets or initiatives.
2
Consequently, there is no evidence to assess the company against any of the 'Planet-Friendly Business' KPIs.
Respect for Cultures & Communities
0
The provided article focuses entirely on Atossa Therapeutics' breast cancer research and development efforts, including statistics on breast cancer and drug potency.
1
It contains no information or specific data points relevant to the company's Respect for Cultures & Communities.
2
Safe & Smart Tech
0
Atossa Therapeutics, Inc. conducts periodic employee training on cyber and information security.
1
The company has not identified risks from known cybersecurity threats that have materially affected it in the last fiscal year, and there are no documented incidents of unauthorized data use.
2
The company implements processes to assess, identify, and manage cybersecurity risks, including vulnerability and data penetration testing, regular review of third-party audits of cloud-based technology vendors, and ongoing regular risk assessments.
3
These processes are managed by a third-party IT vendor and overseen by the Senior Vice President of Administration, with quarterly updates to the Board of Directors.
4
The company is subject to and has a compliance program for state and federal laws, including HIPAA, and international regulations such as the GDPR and UK GDPR.
5
Zero Waste & Sustainable Products
-50
The company achieved a 3.7% reduction in laboratory waste in 2023 compared to 2022.
1
It also reported fully compliant chemical waste management in 2023, with an expenditure of $312,000.
2